NOD2/CARD15 does not influence response to infliximab in Crohn's disease.
Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France.
Vermeire S, et al. Among authors: louis e.
Gastroenterology. 2002 Jul;123(1):106-11. doi: 10.1053/gast.2002.34172.
Gastroenterology. 2002.
PMID: 12105838
Free article.